RxDoctor Payments Data

Mark Hernandez, MD

Internal Medicine · Austin, TXNPI 1093783490

Payments from drug & device makers

$2,923in general payments, 2019–2025

Across 168 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$869
  • Novo Nordisk$839
  • Lilly USA, LLC$476
  • Boehringer Ingelheim$131
  • Astellas Pharma US Inc$105
  • Pfizer$90
  • plus $413 from 13 others

What the payments were for

  • Food & beverage$2,90399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,923 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$146,973
Medicare patients
373
Services billed
5,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$68,332
EliquisApixaban57$65,524
JardianceEmpagliflozin37$43,833
OzempicSemaglutide27$36,443
XareltoRivaroxaban21$28,559
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,293
TrulicityDulaglutide19$19,268
JanuviaSitagliptin Phosphate14$17,590
TradjentaLinagliptin14$10,178
Rosuvastatin Calcium347$4,067
Atorvastatin Calcium388$3,993
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp21$3,919
Wixela InhubFluticasone Propion/Salmeterol15$3,043
Levothyroxine Sodium250$2,754
Tamsulosin Hcl143$2,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$476$87,60080 claims
PfizerEliquis, Paxlovid$90$66,95473 claims
Boehringer IngelheimJardiance, Tradjenta$131$54,01151 claims
Novo NordiskOzempic$839$36,44327 claims
GSKTrelegy Ellipta$869$22,29331 claims
MerckJanuvia$25$17,59014 claims
AbbVieSynthroid$33$1,80732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →